TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy July 26, 2013
TCL Archive DeVita Accepts “Chop Lie” Cancer Control Elements In CCOP; RFA Delays Until After May NCAB Meeting March 12, 1982
